Appropriate @entity1 selection for active surveillance is challenging.Our study of 217 @entity1 demonstrated that the preoperative absolute neutrophil and lymphocyte counts were better predictors of aggressive oncologic features than were the neutrophil-to-lymphocyte ratio in the assessment of low-risk @entity263 @entity1 . Our findings suggest that routine hematologic workup could be used to further stratify low-risk @entity263 @entity1 . INTRODUCTION: The neutrophil-to-lymphocyte ratio (NLR) has emerged as a ubiquitous prognostic biomarker in @entity5 , specifically in @entity1 with metastatic castration-resistant @entity263 ( @entity263 ). We evaluated the clinical utility of the preoperative NLR, absolute neutrophil count (ANC), and @entity6660 ( @entity6660 ) as a risk stratification tool for @entity1 with low-risk @entity263 . MATERIALS AND METHODS: We identified 217 low-risk @entity263 @entity1 with preoperative hematologic data who had met the criteria for active surveillance but had undergone robot-assisted radical prostatectomy at our institution from 2006 to 2015. @entity2357 models were constructed to determine whether the baseline NLR, ANC, and @entity6660 were associated with upstaging, upgrading, and biochemical recurrence (BCR). Survival analyses were performed using the Kaplan-Meier method. RESULTS: On multivariate analysis, a higher prostate-specific antigen level (odds ratio [OR], 1.554; 95% confidence interval [CI], 1.148-2.104), a greater number of positive cores (OR, 2.098; 95% CI, 1.043-2.104), and a higher @entity6660 (OR, 4.311; 95% CI, 1.258-14.770) were associated with upstaging. More importantly, the 5-year biochemical recurrence-free survival was significantly lower in the high ANC group (ANC > 4.0 * 10(9)/L) compared with that of the low ANC group (P = .011). The NLR was not associated with upstaging, upgrading, or BCR in our study cohort (P = .368, P = .573, and P = .504, respectively). The only significant association with upgrading was @entity1 age (OR, 1.106; 95% CI, 1.043-1.173). CONCLUSION: NLR was not useful in predicting adverse pathologic outcomes in our @entity1 with low-risk @entity263 . However, relative @entity4795 might indicate an early manifestation of harboring a more aggressive @entity263 .

Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'PCa'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer-related inflammation'] @entity2357 :: ('MESH:C537770', 'Disease') :: ['Logistic regression'] @entity6660 :: ('MESH:D009845', 'Disease') :: ['ALC', 'absolute lymphocyte count'] @entity4795 :: ('MESH:C563010', 'Disease') :: ['neutrophilia and lymphocytosis']
@entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']
